Literature DB >> 23872845

Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.

Hernani Leonardo Silvestre1, Thomas L Blundell, Chris Abell, Alessio Ciulli.   

Abstract

In fragment-based drug discovery, the weak affinities exhibited by fragments pose significant challenges for screening. Biophysical techniques are used to address this challenge, but there is no clear consensus on which cascade of methods is best suited to identify fragment hits that ultimately translate into bound X-ray structures and provide bona fide starting points for synthesis. We have benchmarked an integrated biophysical approach for fragment screening and validation against Mycobacterium tuberculosis pantothenate synthetase. A primary screen of 1,250 fragments library was performed by thermal shift, followed by secondary screen using one-dimensional NMR spectroscopy (water ligand observed gradient spectroscopy and saturation transfer difference binding experiments) and ultimate hit validation by isothermal titration calorimetry and X-ray crystallography. Our multibiophysical approach identified three distinct binding sites for fragments and laid a solid foundation for successful structure-based elaboration into potent inhibitors.

Entities:  

Keywords:  drug design; hot spots; protein–ligand interactions

Mesh:

Substances:

Year:  2013        PMID: 23872845      PMCID: PMC3740835          DOI: 10.1073/pnas.1304045110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

Authors:  Mei-Chu Lo; Ann Aulabaugh; Guixian Jin; Rebecca Cowling; Jonathan Bard; Michael Malamas; George Ellestad
Journal:  Anal Biochem       Date:  2004-09-01       Impact factor: 3.365

Review 2.  Fragment-based lead discovery: a chemical update.

Authors:  Daniel A Erlanson
Journal:  Curr Opin Biotechnol       Date:  2006-11-03       Impact factor: 9.740

3.  Steady-state and pre-steady-state kinetic analysis of Mycobacterium tuberculosis pantothenate synthetase.

Authors:  R Zheng; J S Blanchard
Journal:  Biochemistry       Date:  2001-10-30       Impact factor: 3.162

4.  Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation.

Authors:  Jonathan D Taylor; Philip J Gilbert; Mark A Williams; William R Pitt; John E Ladbury
Journal:  Proteins       Date:  2007-06-01

5.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase.

Authors:  Alvin W Hung; H Leonardo Silvestre; Shijun Wen; Alessio Ciulli; Tom L Blundell; Chris Abell
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

6.  A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase.

Authors:  E Lucile White; Kristen Southworth; Larry Ross; Sara Cooley; Rachel B Gill; Melinda Ingrum Sosa; Anna Manouvakhova; Lynn Rasmussen; Celia Goulding; David Eisenberg; Thomas M Fletcher
Journal:  J Biomol Screen       Date:  2006-12-14

7.  The design and synthesis of inhibitors of pantothenate synthetase.

Authors:  Kellie L Tuck; S Adrian Saldanha; Louise M Birch; Alison G Smith; Chris Abell
Journal:  Org Biomol Chem       Date:  2006-08-30       Impact factor: 3.876

Review 8.  Antituberculosis drugs: ten years of research.

Authors:  Yves L Janin
Journal:  Bioorg Med Chem       Date:  2007-01-19       Impact factor: 3.641

9.  Active site residues in Mycobacterium tuberculosis pantothenate synthetase required in the formation and stabilization of the adenylate intermediate.

Authors:  Renjian Zheng; Tarum K Dam; C Fred Brewer; John S Blanchard
Journal:  Biochemistry       Date:  2004-06-08       Impact factor: 3.162

10.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.

Authors:  Alessio Ciulli; Glyn Williams; Alison G Smith; Tom L Blundell; Chris Abell
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

View more
  37 in total

Review 1.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

2.  Deploying Fluorescent Nucleoside Analogues for High-Throughput Inhibitor Screening.

Authors:  Leah Seebald; Amaël G E Madec; Barbara Imperiali
Journal:  Chembiochem       Date:  2019-12-03       Impact factor: 3.164

3.  Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.

Authors:  Jennifer La; Catherine F Latham; Ricky N Tinetti; Adam Johnson; David Tyssen; Kelly D Huber; Nicolas Sluis-Cremer; Jamie S Simpson; Stephen J Headey; David K Chalmers; Gilda Tachedjian
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

Review 4.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

5.  Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase.

Authors:  Zhixiang Xu; Wei Yin; Leonardo K Martinelli; Joanna Evans; Jinglei Chen; Yang Yu; Daniel J Wilson; Valerie Mizrahi; Chunhua Qiao; Courtney C Aldrich
Journal:  Bioorg Med Chem       Date:  2014-01-23       Impact factor: 3.641

6.  Small molecule-based targeting of TTD-A dimerization to control TFIIH transcriptional activity represents a potential strategy for anticancer therapy.

Authors:  Virginie Gervais; Isabelle Muller; Pierre-Olivier Mari; Amandine Mourcet; Kumar Tekwani Movellan; Pascal Ramos; Julien Marcoux; Valérie Guillet; Sumaira Javaid; Odile Burlet-Schiltz; Georges Czaplicki; Alain Milon; Giuseppina Giglia-Mari
Journal:  J Biol Chem       Date:  2018-08-01       Impact factor: 5.157

Review 7.  Biophysics in drug discovery: impact, challenges and opportunities.

Authors:  Jean-Paul Renaud; Chun-Wa Chung; U Helena Danielson; Ursula Egner; Michael Hennig; Roderick E Hubbard; Herbert Nar
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

8.  Target-specific NMR detection of protein-ligand interactions with antibody-relayed 15N-group selective STD.

Authors:  Anasztázia Hetényi; Zsófia Hegedűs; Roberta Fajka-Boja; Éva Monostori; Katalin E Kövér; Tamás A Martinek
Journal:  J Biomol NMR       Date:  2016-11-24       Impact factor: 2.835

9.  Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach.

Authors:  Ali Ryan; Elena Polycarpou; Nathan A Lack; Dimitrios Evangelopoulos; Christian Sieg; Alice Halman; Sanjib Bhakta; Olga Eleftheriadou; Timothy D McHugh; Sebastian Keany; Edward D Lowe; Romain Ballet; Areej Abuhammad; William R Jacobs; Alessio Ciulli; Edith Sim
Journal:  Br J Pharmacol       Date:  2017-05-09       Impact factor: 8.739

Review 10.  In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery.

Authors:  Lauro Ribeiro de Souza Neto; José Teófilo Moreira-Filho; Bruno Junior Neves; Rocío Lucía Beatriz Riveros Maidana; Ana Carolina Ramos Guimarães; Nicholas Furnham; Carolina Horta Andrade; Floriano Paes Silva
Journal:  Front Chem       Date:  2020-02-18       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.